2025
Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil
Verruck J, Puga M, de Oliveira R, da Silva P, Charu V, Hedlin H, Lu D, Zhang A, Ritter V, Shaw B, Rosser J, Seidman J, Carter A, Qamar F, Luby S, Garret D, Croda J. Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil. BMJ Public Health 2025, 3: e002331. PMID: 40620571, PMCID: PMC12228459, DOI: 10.1136/bmjph-2024-002331.Peer-Reviewed Original ResearchDose of BNT162b2Fractionated dosesFollow-up visitIgG antibody levelsFollow-upFull doseAntibody levelsAntibody titresDays of follow-upDays post-booster vaccinationBaseline antibody titresClinically protective levelsFollow-up periodHealthy adultsDose of COVID-19 vaccineDays post-boosterBooster dose of BNT162b2Post-booster vaccinationFull-doseBooster doseIgG levelsAZD1222Post-boosterBNT162b2High antibody titres
2024
Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents
de Oliveira L, de Morais I, Marchioro S, de Almeida G, de Almeida de Souza G, da Silva Ferreira T, Rossoni R, de Oliveira Barbosa D, Navarini V, Croda J, Torres A, Simionatto S. Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine 2024, 43: 126494. PMID: 39571350, DOI: 10.1016/j.vaccine.2024.126494.Peer-Reviewed Original ResearchCD8+ T cellsBNT162b2 vaccineT cellsB lymphocytesIncreased levels of B lymphocytesImmune responseCell subpopulationsLevels of B lymphocytesSARS-CoV-2-specific immune responsesMemory B cellsNon-classical monocytesIndigenous adolescentsStatistically significant increaseNK cellsVaccinated adolescentsB cellsNo significant changesBooster doseCohort studyBNT162b2Vaccination scheduleLimited healthcare resourcesImmunogenic responseDemographic dataCOVID-19 vaccineFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines
2023
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend J, Hassler H, Dornburg A. Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting. Journal Of Medical Virology 2023, 95: e28461. PMID: 36602045, DOI: 10.1002/jmv.28461.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Anti-spike IgG antibodiesWaning of antibodiesVaccine boostingBooster vaccinationBreakthrough infectionsAntibody levelsIgG antibodiesMRNA vaccinesProbability of infectionInfectionEndemic transmissionIndividual infectionsPredominant variantCOVID-19 pandemicMessenger RNAAntibodiesDisease spreadBNT162b2HospitalizationMorbidityVaccinationWidespread uptakeVaccineMortality
2022
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply